Desvenlafaxine Succinate Tablet, Extended Release
Product Images NDC 33342-388

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 33342-388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine-er-tab-100mg-30s (Desvenlafaxine Er Tab 100mg 30s)

Label for Desvenlafaxine Extended-Release Tablets 100 mg by Macleods Pharmaceuticals Limited. The label states each tablet contains 152 mg desvenlafaxine succinate equivalent to 100 mg desvenlafaxine. It includes storage instructions, manufacturer details, and a note to dispense an accompanying Medication Guide. Package contains 30 tablets.*

FDA Label Image

Desvenlafaxine-er-tab-100mg-90s (Desvenlafaxine Er Tab 100mg 90s)

Desvenlafaxine Succinate Extended-Release Tablets 100 mg label for oral use, manufactured by Macleods Pharmaceuticals Limited. The label indicates each tablet contains 152 mg of desvenlafaxine succinate equivalent to 100 mg desvenlafaxine and comes in a package of 90 tablets. Storage instructions, NDC number 33342-389-10, and manufacturer details are also visible.*

FDA Label Image

Desvenlafaxine-er-tab-100mg-cartons (Desvenlafaxine Er Tab 100mg Cartons)

Desvenlafaxine Extended-Release Tablets 100 mg packaging label by Macleods Pharmaceuticals Limited. The label shows the strength 100 mg prominently, includes NDC 33342-389-12, and states there are 100 tablets (10 x 10 unit dose). Manufacturer information lists Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India. The label cautions that the blister pack is not child resistant and provides storage instructions.*

FDA Label Image

Desvenlafaxine-er-tab-50mg-30s (Desvenlafaxine Er Tab 50mg 30s)

Label for Desvenlafaxine Extended-Release Tablets, 50 mg, by Macleods Pharmaceuticals Limited. The label indicates each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. The packaging also includes manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India, with a package size of 30 tablets.*

FDA Label Image

Desvenlafaxine-er-tab-50mg-90s (Desvenlafaxine Er Tab 50mg 90s)

Label for Desvenlafaxine Extended-Release Tablets 50 mg by Macleods Pharmaceuticals Limited. The label shows the active ingredient amount (50 mg desvenlafaxine), storage instructions (20° to 25°C with excursions permitted), and includes barcode and manufacturer information. The package contains 90 tablets.*

FDA Label Image

Desvenlafaxine-er-tab-50mg-cartons (Desvenlafaxine Er Tab 50mg Cartons)

Desvenlafaxine Succinate 50 mg extended-release tablets packaging label includes front and side panels. The label features the product name, strength (50 mg), and quantity (100 tablets, 10 x 10 unit dose). It is labeled for oral use, manufactured by Macleods Pharmaceuticals Limited and marketed by Macleods Pharma USA, Inc. The label also includes storage instructions and a barcode.*

FDA Label Image

Desvenlafaxine-fig-01 (Desvenlafaxine Fig 01)

A pharmacokinetic impact figure showing the geometric mean ratio with 90% confidence intervals for Desvenlafaxine based on intrinsic factors including renal impairment (mild to ESRD), hepatic impairment (mild to severe), and population variables such as gender and age groups (65-75 years, >75 years). The chart presents Cmax and AUC changes relative to reference values across these conditions.*

FDA Label Image

Desvenlafaxine-fig-02 (Desvenlafaxine Fig 02)

A horizontal bar chart illustrating the effect of the CYP3A4 inhibitor ketoconazole on desvenlafaxine pharmacokinetics. The chart shows geometric mean ratios with 90% confidence intervals for Cmax and AUC relative to a reference, indicating an increase in desvenlafaxine exposure when co-administered with ketoconazole.*

FDA Label Image

Desvenlafaxine-fig-03 (Desvenlafaxine Fig 03)

A forest plot chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters (Cmax and AUC) for desvenlafaxine interaction with various drugs including desipramine, midazolam, tamoxifen, and aripiprazole across different dosages (50 mg, 100 mg, 400 mg). The chart indicates changes relative to reference values for CYP2D6 and CYP3A4 substrates.*

FDA Label Image

Desvenlafaxine-fig-04 (Desvenlafaxine Fig 04)

A line graph showing the estimated proportion of patient relapses over time in days since randomization from Study 5. It compares Desvenlafaxine 50 mg versus placebo, with the Y-axis representing the estimated proportion of patients with relapse (%) and the X-axis showing time to relapse in days. The Desvenlafaxine 50 mg line is lower than the placebo line throughout the period up to around 180 days.*

FDA Label Image

Desvenlafaxine-fig-05 (Desvenlafaxine Fig 05)

This chart shows the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine extended-release tablets and placebo. The x-axis represents time to relapse up to 180 days, and the y-axis shows the estimated relapse proportion up to 50%. The graph includes two lines: one for Desvenlafaxine (blue solid line) and another for placebo (red dashed line), illustrating a lower relapse rate for the Desvenlafaxine group.*

FDA Label Image

Str (Desvenlafaxine Str)

Chemical structure of Desvenlafaxine Succinate, showing the molecular arrangement including aromatic rings, hydroxyl groups, a dimethylamine moiety, and the succinate and water components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.